McKesson Corporation is a prominent global provider of healthcare services, operating extensively in both the United States and international markets. Its diverse operations are strategically organized into four key business segments. The U.S. Pharmaceutical division plays a crucial role in the distribution of a comprehensive array of pharmaceutical products, encompassing branded, generic, specialty, biosimilar, and over-the-counter medications, alongside other health-related merchandise. This segment also delivers specialized support to community-based oncology and other specialty medical practices through practice management tools, technology solutions, clinical guidance, and broader business services. Furthermore, it assists pharmacies with consulting, outsourcing, and technology services, while also furnishing financial, operational, and clinical software solutions. Internationally, the company's dedicated segment provides distribution and support services to wholesale, institutional, and retail clients across 13 European nations and Canada. The Medical-Surgical Solutions unit is focused on supplying healthcare providers with essential medical-surgical products, sophisticated logistics management, and a variety of associated services. Finally, the Prescription Technology Solutions (RxTS) segment is designed to address complex medication challenges for patients. It collaborates with biopharmaceutical companies and life sciences partners to improve patient journeys, leveraging innovative solutions for medication access and adherence by connecting pharmacies, healthcare providers, payers, and biopharma entities. This segment further offers third-party logistics and wholesale distribution assistance. Founded in 1833, McKesson Corporation maintains its corporate headquarters in Irving, Texas.

Rutledge Napoleon B JR

TYLER BRIAN S.

Rodgers Thomas L

Smith LeAnn B

Lau Michele

Martinez Maria

McKesson (MCK) has outperformed the broader market with a +15.6% return over the past month, compared to the S&P 500's +0.7%. The company shows solid fundamentals with expected earnings growth of +14.3% for the current fiscal year and +11.8% for the next year. However, with a Zacks Rank #3 (Hold) rating and minimal recent changes to earnings estimates (+0.1-0.3%), the stock is expected to perform in line with the broader market in the near term. The company trades at a valuation discount to peers (Grade B) and has consistently beaten consensus estimates.

Is Trending Stock McKesson Corporation (MCK) a Buy Now?

Amgen and Bristol Myers Squibb represent different investment approaches in pharmaceuticals. Amgen demonstrates stronger revenue growth (~10% YoY) with higher profitability margins (21%) but trades at a premium valuation (P/E 26.4x). Bristol Myers Squibb offers significantly lower valuation (P/E 12.96x) and higher dividend yield (4.1%) with stronger free cash flow ($12.8B), though facing revenue headwinds and generic competition. For long-term dividend-focused investors, Bristol Myers Squibb is recommended despite near-term challenges.

Amgen vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026?

McKesson (MCK) closed at $1,030.12, up 1.95%, outperforming the S&P 500's 0.28% gain. The prescription drug distributor has gained 13.98% over the past month. Analysts project Q4 2026 earnings of $10.69 per share (8.42% YoY growth) and full-year earnings of $44.71 per share (14.32% YoY growth). MCK trades at a Forward P/E of 22.6, above its industry average of 17.17, and holds a Zacks Rank #3 (Hold) rating.

McKesson (MCK) Outperforms Broader Market: What You Need to Know

Europe's EHR market is expected to grow from US$8.05 billion in 2024 to US$15.37 billion by 2031, driven by AI adoption, cloud-based solutions, and government digital health initiatives. Cloud-based systems lead the market, with acute EHR and clinical records as primary segments. Germany is the largest market contributor, supported by national digital strategy and mandatory e-prescriptions. Leading vendors are investing in product innovation, partnerships, and M&A to strengthen market presence.

Europe Electronic Health Record (EHR) Market Size, Share, Trends, and Forecast, 2021 - 2031 | AI and Cloud Adoption Drive 9.9% CAGR, Creating a US$ 15.37 Billion Opportunity

The U.S. economy showed mixed signals with rising inflation (3.7% headline, 2.6% core) and geopolitical tensions pressuring markets. The Nasdaq fell 4.1% while the Dow gained 0.29%, reflecting investor preference for blue-chip stocks over tech. Despite market uncertainty, Zacks' research-driven rating systems demonstrated strong performance, with Valero Energy gaining 29.7% post-upgrade, Palantir surging 40.5% over 12 weeks, and the Zacks Rank #1 portfolio outperforming the S&P 500 by 3.9 percentage points year-to-date.

Beat the Market the Zacks Way: Valero Energy, Hagerty, Palantir in Focus

AbbVie and Pfizer are compared as healthcare investment options in 2026. AbbVie has successfully navigated patent cliff challenges with strong growth from Skyrizi and Rinvoq offsetting Humira losses, while Pfizer is rebuilding its pipeline around obesity drugs and awaiting key pipeline readouts. The article recommends AbbVie as the clearer choice for investors seeking current pharmaceutical exposure, though both companies face biosimilar competition and regulatory pressures.

AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?

The Largest Source of Financially Related Content and Creators | Marketing Partners w/ @nasdaq @Cboe and more.

WOLF

29. Lake Michigan elitist. Seller of cloud services who likes stocks

jiggycapital

All stocks and economy. All the time. Except when I mix in references to sports and pop culture. Senior markets analysis writer @barronsonline. Ex-@CNNBusiness.

Paul R. La Monica

Co-Founder @21RatesHQ and @MeetScanley | Hosting @DailyStackHQ 
Deep stock research + Bitcoin | BTC class 2017

McKesson Corporation (MCK) Stock Price, Analysis & Trade Signals